|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LMP1 effects were also evaluated in the EBV-negative B-lymphoma cell line BL41 and the EBV-positive Burkitt's lymphoma cell line, Daudi (Daudi is deleted for EBNA-2 and does not express LMP).
|
2157887 |
1990 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LMP promoter cat gene constructs were more active in a Burkitt's lymphoma cell line latently infected with the B95 EBV strain than in the same cells latently infected with the P3HR1 EBV strain.
|
2157069 |
1990 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results suggest that expression of LMP1 at levels which are compatible with immortalization of normal B-cells antagonizes the ability of BL cells to grow in vitro and in vivo, and illustrate a possible mechanism by which down-regulation of this viral antigen may favor tumorigenicity in EBV-carrying BLs.
|
1322379 |
1992 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Latency III (Lat III) in group III BL and EBV-transformed lymphoblastoid cell lines (LCLs) is characterized by expression of EBNAs 1, 2, 3a, 3b, 3c, and -LP from mRNAs driven by the Cp or Wp promoter and of the latent membrane proteins (LMPs 1, 2A, and 2B) from mRNAs driven by the LMP promoters.
|
1310556 |
1992 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The LMP1 and EBNA2 genes were transiently expressed from heterologous promoters in two human T-cell lines (HPB-ALL and Jurkat), two human cell lines of the myeloid lineage (K562 and U937), one type I Burkitt's lymphoma cell line (Rael) and in human primary T cells and B-cell chronic lymphocytic leukemia cells.
|
8093369 |
1993 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we report that clones of the BL line Mutu that differ in expression of LMP 1 also show a differential methylation pattern of the LMP 1 regulatory sequences: this region is hypomethylated in an LMP 1 expressing (group III) clone but methylated in a group I clone that does not express LMP 1.
|
8178450 |
1994 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines.
|
8157362 |
1994 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EBV latent genes, latent membrane protein 1 (LMP1) and the EBV nuclear antigen 2 (EBNA2), were detected by immunohistochemistry in the Wiskott-Aldrich lymphoma but not in an EBV-positive Burkitt's lymphoma, implying that host immune factors could influence EBV gene expression.
|
8112728 |
1994 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The latent membrane protein 1 (LMP1) is likely to play a determinant role in this process since this EBV encoded protein has oncogenic properties and is usually expressed in EBV-associated lymphoproliferative diseases (LPD), except Burkitt's lymphoma.
|
9160892 |
1997 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The absence of del-LMP-1 within all EBV+ BL cases is consistent with the view that del-LMP-1 is not involved in the pathogenesis of BL, and the presence of del-LMP-1 in EBV+ cases of BL reported in other studies may likely reflect the prevalence of a viral strain containing the 30-bp deletion within the respective population studied.
|
9042791 |
1997 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we established an in vitro system representing the Burkitt's lymphoma (BL)-type Epstein-Barr virus (EBV) infection which is characterized by expression of EBV-determined nuclear antigen 1 (EBNA-1) and absence of EBNA-2 and latent membrane protein 1 (LMP1) expression.
|
9765461 |
1998 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using a panel of EBV+ and EBV- Burkitt lymphoma (BL) cell lines, a significant correlation was detected between the expression of the EBV latency gene LMP1 and the occurrence of spontaneous tumor regression in athymic mice.
|
9516150 |
1998 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unusually high frequency of a 69-bp deletion within the carboxy terminus of the LMP-1 oncogene of Epstein-Barr virus detected in Burkitt's lymphoma of Turkish children.
|
9823956 |
1998 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because the effects of LMP1 have been most closely studied in human Burkitt Lymphoma (BL) cell lines retaining a tumor biopsy-like phenotype in vitro, we have examined the response of a panel of such lines to CD40 ligation.
|
10092782 |
1999 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies of EBV-converted and stably transfected BL cell lines demonstrated that the EBV gene LMP-1 is neither necessary nor sufficient to block the TGF-beta1 response.
|
10811940 |
2000 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using an EBV-negative Burkitt's lymphoma cell line in which the expression of EBV latent membrane protein 1 (LMP1) is inducibly regulated by tetracycline, we demonstrate that LMP1 expression coincides with a dramatic increase in the level of bfl-1 mRNA.
|
10864681 |
2000 |
|
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study highlights the similarities and differences in the clinical presentation and EBV association of BL in two developing countries and also indicates that the subtype of EBV and prevalence of the LMP-1 deletion may reflect the predominant subtype in a particular population.
|
11342313 |
2000 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that IL-10 was specifically induced by the EBV-latent membrane protein 1 (LMP1) in Burkitt's lymphoma (BL) cell lines BL2 and BL41.
|
11162833 |
2001 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have shown that Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) is uniquely able to up-regulate the expression of the peptide transporters (referred to as TAP-1 and TAP-2) and major histocompatibility complex (MHC) class I in Burkitt's lymphoma (BL) cell lines.
|
11799186 |
2002 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Z-43 cells expressed high levels of LMP1 (immunoblot) and lymphotoxin (ELISA); the EBV-positive Burkitt's lymphoma line Daudi expressed neither LMP1 nor lymphotoxin.
|
14523478 |
2003 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histone deacetylase inhibitor-stimulated endogenous LMP-1 also induced CCL20 expression in an EBV-positive BL cell line.
|
16409294 |
2006 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines.
|
16332968 |
2006 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Northern blotting revealed high levels of miR-146a and miR-155 in the Burkitt's lymphoma cell line Jijoye which expresses LMP1 while the LMP1-deficient P3HR1 mutant derived from Jijoye expresses less miR-146a or miR-155.
|
18347435 |
2007 |
|
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Latency type III infection of Burkitt's lymphoma cell lines with immortalization-competent virus expressing the full set of latency genes selectively decreased the expression of SERCA3 protein, whereas infection with immortalization-deficient virus that does not express the EBNA2 or LMP-1 viral genes was without effect.
|
19650915 |
2009 |
|
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we show that LMP1 negatively regulates a major oncogene, TCL1, in diffuse large B-cell lymphoma (DLBCL) and BL cells.
|
19966860 |
2010 |